To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Intercell tops up $50m funding round
The Austrian vaccine developer has landed the largest biotechnology financing round for two years with lead investments from MPM Capital and Global Life Science Ventures.
